Article info

Download PDFPDF

Prospective trial of natalizumab personalised extended interval dosing by therapeutic drug monitoring in relapsing-remitting multiple sclerosis (NEXT-MS)
Free

Authors

  1. Correspondence to Dr Marcus Koch, Clinical Neurosciences, University of Calgary, Calgary, AB T2N 1N4, Canada; mwkoch{at}ucalgary.ca
View Full Text

Citation

Koch M
Prospective trial of natalizumab personalised extended interval dosing by therapeutic drug monitoring in relapsing-remitting multiple sclerosis (NEXT-MS)

Publication history

  • Received October 26, 2023
  • Accepted October 29, 2023
  • First published November 14, 2023.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.